Panhandle Real Estate Investments Publishes Southport Case Study on Inherited Home, Squatters, and Foreclosure Timeline

Panhandle Real Estate Investments' Southport case study: "Inherited House With Squatters + Foreclosure… We Still Closed It."

Panhandle Real Estate Investments has released a case study describing a Southport, Florida transaction involving an inherited property that was occupied by squatters and facing a foreclosure timeline. The company says the closing required coordination among heirs, including documentation needs related to an incarcerated co-heir, and highlights process considerations for families dealing with probate-related complications. The full case study is published on ThePanhandleHomeBuyer.com.

PANAMA CITY, FL - January 30, 2026 - Panhandle Real Estate Investments announced the publication of a new real-life case study highlighting how the company helped a Southport, Florida family successfully close on an inherited mobile home that was occupied by squatters and facing foreclosure.

The story outlines a situation involving two heirs, ongoing occupancy issues, and a foreclosure timeline that continued moving forward while the family worked through probate-related complications. One of the heirs was incarcerated, which required the coordination of a notarized power of attorney to move the transaction forward. The home also required significant repairs, including soft spots in flooring, major kitchen work, and interior upgrades making a traditional listing unrealistic for the seller.

“Most people have no idea what to do when they inherit a property and immediately get hit with foreclosure pressure and occupancy problems,” said Peyton Saluto, founder of Panhandle Real Estate Investments. “Our goal is to handle the obstacles, simplify the process, and help families move on with a clean, respectful solution.”

According to the case study, the team worked through key challenges including:

• Coordinating documentation and signatures with an incarcerated co-heir through a notarized power of attorney

• Assisting the seller in navigating a lawful eviction process for squatters

• Communicating and coordinating around the foreclosure timeline to allow time for closing

• Completing due diligence and renovation planning so the seller could sell as-is without delays

The final outcome was a closed deal that allowed the seller to avoid repairs, reduce stress, and exit a difficult situation with clarity and peace of mind.

The full case study, “Inherited House in Foreclosure with Squatters? Here’s How We Helped a Southport Family Close the Deal,” is available here: https://www.thepanhandlehomebuyer.com/blog/inherited-house-in-foreclosure-with-squatters-heres-how-we-helped-a-southport-family-close-the-deal/

About Panhandle Real Estate Investments

Panhandle Real Estate Investments is a Florida Panhandle-based real estate solutions company led by founder Peyton Saluto. The company helps homeowners sell properties as-is, often in complex situations involving probate, foreclosure pressure, inherited properties, distressed homes, and challenging occupancy issues. The team is based in the Panama City / Southport market and serves homeowners throughout the surrounding area.

To request a no-obligation cash offer, visit https://www.thepanhandlehomebuyer.com or call 850-778-2212.

Media Contact
Company Name: Panhandle Real Estate Investments
Contact Person: Peyton Saluto
Email:Send Email
Phone: (850) 778-2212
City: Panama City
State: FL
Country: United States
Website: https://www.thepanhandlehomebuyer.com/blog/inherited-house-in-foreclosure-with-squatters-heres-how-we-helped-a-southport-family-close-the-deal/

Triple Negative Breast Cancer Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Triple Negative Breast Cancer pipeline constitutes 165+ key companies continuously working towards developing 170+ Triple Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Triple Negative Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Triple Negative Breast Cancer Market.

 

The Triple Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Get a Free Sample PDF Report to know more about Triple Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight

 

Some of the key takeaways from the Triple Negative Breast Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Triple Negative Breast Cancer treatment therapies with a considerable amount of success over the years.

• Triple Negative Breast Cancer companies working in the treatment market are Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others, are developing therapies for the Triple Negative Breast Cancer treatment

• Emerging Triple Negative Breast Cancer therapies in the different phases of clinical trials are- SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others are expected to have a significant impact on the Triple Negative Breast Cancer market in the coming years.

• In January 2026, CytoDyn (OTCQB: CYDY) announced that an anonymous donor has provided funding to support an Expanded Access Program (EAP) allowing patients with triple-negative breast cancer (TNBC) to receive leronlimab. The company has partnered with WEP Clinical as the CRO and plans to open the program for patient referrals in March 2026, pending FDA approval of a revised protocol. The EAP is designed for patients who have exhausted approved therapies and do not qualify for ongoing clinical trials. The program may also offer insights into PD-L1 induction after leronlimab and potential combination strategies with immune checkpoint inhibitors. Additional details for physicians and patients will be shared on the company’s website as the program progresses.

• In September 2025, ProteinQure, a Toronto-based biotech specializing in computational peptide drug discovery, announced the first patient has been dosed in its Phase I clinical trial of PQ203, a novel peptide therapeutic for advanced metastatic solid tumors. This marks the company’s first internally developed AI-designed peptide therapy to reach the clinic, just three years after the program’s initiation. PQ203 consists of a peptide targeting the Sortilin receptor linked to the cytotoxic agent MMAE. Since the Sortilin receptor is highly expressed in diseased tissue of Triple Negative Breast Cancer (TNBC) patients, PQ203 has shown strong efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), the current standard of care for metastatic TNBC.

• In January 2025, The Novotech Triple Negative Breast Cancer Clinical Trial Report highlighted ongoing drug development across multiple phases, with 78 trials in Phase I, 97 in Phase II, and 12 in Phase III. Key advancements include targeted therapies such as PARP inhibitors, immune checkpoint inhibitors (ICIs), and innovative antibody-drug conjugates (ADCs). Additionally, combination approaches that integrate immunotherapy, chemotherapy, and targeted treatments are improving overall treatment effectiveness.

• In November 2024, A novel treatment strategy developed at Roswell Park Comprehensive Cancer Center demonstrated encouraging results in a Phase 1 clinical trial for patients with triple-negative breast cancer (TNBC), the most aggressive form of the disease.

• In February 2024, Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-drug conjugate for treating advanced triple-negative breast cancer (TNBC) in adults who have undergone at least two prior treatments for metastatic disease. It is also indicated for pre-treated HR+/HER2- metastatic breast cancer patients and second-line metastatic TNBC patients who have received endocrine-based therapy and at least two other systemic therapies.

 

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is characterized by a tumor that has negative levels of estrogen and progesterone (ER/PR), as determined by immunohistochemistry (IHC), and neither immunohistochemistry (IHC) nor fluorescence in situ hybridization (FISH) has detected overexpression of the HER2 gene.

 

Explore the latest Triple Negative Breast Cancer pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Triple Negative Breast Cancer Clinical Trials

 

Emerging Triple Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

• SKB264: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

• AK117: Akeso Biopharma

• PLX038: ProLynx

• mRNA-2752: ModernaTX, Inc.

• OTS167PO: OncoTherapy Science

• PMD-026: Phoenix Molecular Designs

• X4P-001: Abbisko Therapeutics

• BLEX 404: BioLite, Inc.

• ZEN003694 +Talazoparib: Zenith Epigenetics

• mprime PGG: HiberCell, Inc.

• IPI-549: Infinity Pharmaceuticals

• Trilaciclib: G1 Therapeutics, Inc

• Camrelizumab: Jiangsu HengRui Medicine Co., Ltd

• HLX10: Shanghai Henlius Biotech

 

Triple Negative Breast Cancer Route of Administration

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

Triple Negative Breast Cancer Molecule Type

Triple Negative Breast Cancer Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Triple Negative Breast Cancer Pipeline Therapeutics Assessment

• Triple Negative Breast Cancer Assessment by Product Type

• Triple Negative Breast Cancer By Stage and Product Type

• Triple Negative Breast Cancer Assessment by Route of Administration

• Triple Negative Breast Cancer By Stage and Route of Administration

• Triple Negative Breast Cancer Assessment by Molecule Type

• Triple Negative Breast Cancer by Stage and Molecule Type

 

DelveInsight's Triple Negative Breast Cancer Report covers around 170+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Triple Negative Breast Cancer product details are provided in the report. Download the Triple Negative Breast Cancer pipeline report to learn more about the emerging Triple Negative Breast Cancer therapies

 

Some of the key companies in the Triple Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for Triple Negative Breast Cancer are - ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.

 

Triple Negative Breast Cancer Pipeline Analysis:

The Triple Negative Breast Cancer pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Triple Negative Breast Cancer with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer Treatment.

• Triple Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Triple Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Triple Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Triple Negative Breast Cancer drugs and therapies

 

Triple Negative Breast Cancer Pipeline Market Drivers

• Increase in the prevalence of Triple Negative Breast Cancer, increasing Research and Development activities are some of the important factors that are fueling the Triple Negative Breast Cancer Market.

 

Triple Negative Breast Cancer Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the Triple Negative Breast Cancer Market growth.

 

Scope of Triple Negative Breast Cancer Pipeline Drug Insight

• Coverage: Global

• Key Triple Negative Breast Cancer Companies: Sichuan Kelun-Biotech Biopharmaceutical, Akeso Biopharma, ProLynx, ModernaTX, Inc., OncoTherapy Science, Phoenix Molecular Designs, Abbisko Therapeutics, BioLite, Inc., Zenith Epigenetics, HiberCell, Inc., Infinity Pharmaceuticals, G1 Therapeutics, Inc, Jiangsu HengRui Medicine Co., Ltd, Shanghai Henlius Biotech, and others

• Key Triple Negative Breast Cancer Therapies: SKB264, AK117, PLX038, mRNA-2752, OTS167PO, PMD-026, X4P-001, BLEX 404, ZEN003694 +Talazoparib, mprime PGG, IPI-549, Trilaciclib, Camrelizumab, HLX10, and others

• Triple Negative Breast Cancer Therapeutic Assessment: Triple Negative Breast Cancer current marketed and Triple Negative Breast Cancer emerging therapies

• Triple Negative Breast Cancer Market Dynamics: Triple Negative Breast Cancer market drivers and Triple Negative Breast Cancer market barriers

 

Request for Sample PDF Report for Triple Negative Breast Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1. Triple Negative Breast Cancer Report Introduction

2. Triple Negative Breast Cancer Executive Summary

3. Triple Negative Breast Cancer Overview

4. Triple Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. Triple Negative Breast Cancer Pipeline Therapeutics

6. Triple Negative Breast Cancer Late Stage Products (Phase II/III)

7. Triple Negative Breast Cancer Mid Stage Products (Phase II)

8. Triple Negative Breast Cancer Early Stage Products (Phase I)

9. Triple Negative Breast Cancer Preclinical Stage Products

10. Triple Negative Breast Cancer Therapeutics Assessment

11. Triple Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Triple Negative Breast Cancer Key Companies

14. Triple Negative Breast Cancer Key Products

15. Triple Negative Breast Cancer Unmet Needs

16 . Triple Negative Breast Cancer Market Drivers and Barriers

17. Triple Negative Breast Cancer Future Perspectives and Conclusion

18. Triple Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Lightweight Aggregates Market Size Analysis, Emerging Demand, Competitive Share, Key Trends, and Growth Forecast to 2030

The Lightweight Aggregates Market is gaining momentum due to rising demand for sustainable construction materials and energy-efficient buildings. Growth is supported by infrastructure development and urbanization across regions. Key players such as Holcim, CEMEX, Heidelberg Materials, Arcosa Inc., and Saint-Gobain are focusing on capacity expansion, lightweight concrete solutions, and eco-friendly product innovation.

The lightweight aggregates market size is projected to grow from USD 13.14 billion in 2025 and is projected to reach USD 15.52 billion by 2030, at a CAGR of 3.4%. The report explores comprehensive and insightful information about various key factors like regional growth, segmentation, lightweight aggregates market trends, CAGR, business revenue status of top key players and drivers. The lightweight aggregates market will grow due to increasing demand for sustainable materials. Governments are promoting green building practices and strict environmental regulations. This will promote the use of lightweight aggregates. Rapid urbanization and infrastructure development in emerging economies are driving demand for lightweight aggregates. The growing preference for eco-friendly in residential, commercial, and industrial projects will further boost the market. Government investments in smart cities are expected to drive the demand for lightweight aggregates.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=8177489

Pumice accounted for the fourth largest share in the global lightweight aggregates market

Pumice has lightweight properties and has excellent performance in construction applications. Pumice is used in concrete production which helps in reducing the weight of infrastructure. It is resistant to chemicals, and moisture, thus it is a preferred choice for construction projects. Many countries are encouraging the use of eco-friendly building materials, this will propel the demand for pumice. As urbanization and infrastructure development are growing the demand for pumice will remain strong.

By end-use industry, infrastructure accounts for the second-largest share of the lightweight aggregates market

Infrastructure applications are growing due to large-scale construction projects such as bridges, roads, and tunnels. They help in reducing the weight of concrete structures. This weight reduction is important for bridges and highways as it minimizes stress on the foundations. Governments worldwide are investing in infrastructure modernization which will increase the demand for lightweight aggregates. As urbanization and smart city development are growing, the demand for lightweight aggregates in infrastructure projects will increase.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=8177489

Asia Pacific for the third largest share in the global lightweight aggregates market

Asia Pacific is the third-largest region because of rapid urbanization and infrastructure development. Countries like China, and India are investing in new roads and airports. The increasing demand for affordable housing and smart city projects in emerging economies is driving the use of lightweight aggregates in residential and commercial construction. Governments in the Asia Pacific are promoting eco-friendly building materials.

Lightweight Aggregates Companies

The report profiles key players such as Arcosa, Inc. (US), Boral Industries Inc. (Australia), CEMEX S.A.B. de C.V. (Mexico), Leca International (Denmark), and Stalite Lightweight Aggregate (US).

Arcosa Inc. (US) is a provider of infrastructure-related products and solutions, serving the construction, engineered structures, and transportation markets across North America. Incorporated in Delaware in 2018, Arcosa operates as an independent, publicly traded company listed on the New York Stock Exchange. The company operates through three main business segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment offers a range of products, including natural and recycled aggregates, specialty materials such as lightweight aggregates and plaster, and trench shields and shoring products. Its primary markets include infrastructure projects (such as roads, bridges, and other public works), residential and non-residential construction, agriculture, specialty building products, and underground construction. Arcosa Specialty Materials mines, mills, processes, and distributes lightweight aggregates, plaster products, gypsum, limestone minerals, and other downstream products for the food and building industries. Arcosa Lightweight is a part of the Arcosa family of companies and is the largest producer of rotary kiln expanded shale and clay lightweight aggregate in North America, with production facilities located in Alabama, Arkansas, California, Colorado, Louisiana, Indiana, Kentucky, and Texas.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=8177489

Boral Industries Inc. (Australia) is the largest vertically integrated construction materials company in Australia, with an extensive network of valued quarry and cement infrastructure, as well as bitumen, construction materials recycling, asphalt, and concrete batching operations. The company's integrated network includes 360 operating sites and serves over 14,000 customers. Boral Australia produces a wide range of cementitious materials for various applications. Its upstream cement operations involve manufacturing clinker from its limestone, importing clinker for cement grinding, and processing fly ash and slag as supplementary cementitious materials

Cemex S.A.B. DE C.V. (Mexico) is aleading global provider of construction materials and solutions. The company offers a wide range of products, including cement, ready-mix concrete, aggregates, and urbanization solutions in growing markets worldwide. Cemex operates 60 cement and grinding plants, 232 aggregate sites, and 262 land distribution centers. Its business segments include cement, ready-mix concrete, urbanization solutions, and aggregates. Cemex delivers high-performance, innovative, and sustainable cement solutions, offering various types of cement such as Rugby Bagged Cement, Bulk Cement, and Fly Ash. Cemex has a strong global presence, with operations in the US, Mexico, South and Central America, the Caribbean, Europe, the Middle East, Asia, Africa, and other regions.

Leca International (Denmark) is a Saint-Gobain company specializing in the development, production, and marketing of Leca® products. Its primary product, Leca® Lightweight Aggregate (Leca® LWA), is a versatile, durable, and easy-to-use solution. Leca operates with a strong local presence in over 12 European countries. Production facilities are in Denmark, Sweden, Finland, Norway, Poland, and Portugal, while sales offices are established in the UK, Spain, Germany, Lithuania, Estonia, and Latvia.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/lightweight-aggregates-market-8177489.html

Osteoarthritis Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Merck, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Osteoarthritis pipeline constitutes 100+ key companies continuously working towards developing 110+ Osteoarthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Osteoarthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Osteoarthritis Market.

 

The Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Get a Free Sample PDF Report to know more about Osteoarthritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/osteoarthritis-pipeline-insight

 

Some of the key takeaways from the Osteoarthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Osteoarthritis treatment therapies with a considerable amount of success over the years.

• Osteoarthritis companies working in the treatment market are Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics, and others, are developing therapies for the Osteoarthritis treatment

• Emerging Osteoarthritis therapies in the different phases of clinical trials are- M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others are expected to have a significant impact on the Osteoarthritis market in the coming years.

• In January 2026, 4Moving Biotech (4MB), a clinical-stage biotechnology company focused on developing next-generation, disease-modifying therapies for osteoarthritis (OA), announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for 4P004. This clearance allows the Phase 2a INFLAM MOTION clinical trial to expand into the United States. The FDA approval represents a strategic milestone in 4MB’s global clinical efforts across Europe, Canada, and now the U.S., strengthening the company’s position as a leader in the pursuit of the first disease-modifying osteoarthritis drug (DMOAD) for patients worldwide.

• In November 2025, Novo Nordisk has released new findings from the OASIS 4 Phase 3 trial, which investigated various patient populations and hypotheses, further supporting the potential of this therapy. Injectable semaglutide 2.4 mg, marketed as Wegovy®, is approved in the EU as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity. Wegovy® is also approved for pediatric patients aged 12 and older with an initial BMI at or above the 95th percentile and body weight over 60 kg. The label highlights clinical evidence of major adverse cardiovascular event (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, and pain relief for knee osteoarthritis.

• In May 2025, Lipogems announced the successful completion of its ARISE I U.S. FDA IDE Study, with the final patient visit now concluded. This marks a significant milestone in progressing Lipogems as a treatment option for knee osteoarthritis (OA) in patients who are not eligible for or ready to undergo knee replacement. The double-blind, randomized controlled trial included 173 participants across 18 leading U.S. clinical sites. The study's primary focus is on assessing pain relief and functional improvement 12 months after injection. Results on efficacy and safety are anticipated by late 2025.

• In May 2025, Genascence Corporation, a clinical-stage biotech firm focused on transforming musculoskeletal disease treatment through gene therapy, reported positive 12-month safety and biomarker findings from its Phase 1b DONATELLO trial of GNSC-001. This investigational gene therapy targets interleukin 1 (IL-1) for treating knee osteoarthritis (OA). The 12-month results confirmed the trial met its primary endpoint, showing consistent safety and tolerability across all tested doses. Additionally, the study met a key secondary endpoint, demonstrating sustained IL-1Ra expression in synovial fluid, reinforcing the six-month data previously reported.

• In May 2025, Moximed, a pioneering medical device company focused on enhancing care for individuals with knee osteoarthritis (OA), announced that the first patients have been treated in its latest randomized controlled trial (RCT). The MOTION study is a prospective, multicenter trial designed to compare the effectiveness of the MISHA Knee System against non-surgical treatment options in patients with medial knee osteoarthritis.

• In April 2025, Pacira BioSciences reported that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed long-lasting improvements in knee pain, mobility, and stiffness for up to two years in a Phase I trial. Participants received a single local injection of the therapy. The study included 72 individuals aged 30 to 80, categorized based on the severity of their knee osteoarthritis using the Kellgren-Lawrence (K/L) grading system.

• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.

• In March 2025, RION, a clinical-stage company specializing in regenerative medicine and exosome-based therapies, announced the enrollment of the first patient in its Phase 1b trial of Purified Exosome Product™ (PEP™) for treating Knee Osteoarthritis (OA). This marks a significant step in RION’s mission to develop cutting-edge regenerative solutions for unmet medical needs.

• In September 2024, Cytonics announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.

 

Osteoarthritis Overview

Osteoarthritis (OA) is a chronic joint disorder characterized by the gradual breakdown of cartilage, leading to pain, stiffness, swelling, and reduced mobility. It most commonly affects the knees, hips, hands, and spine. OA is influenced by age, genetics, obesity, joint injuries, and repetitive stress on joints. While it is not curable, treatments focus on symptom relief, improving joint function, and slowing disease progression through medications, physical therapy, lifestyle modifications, and, in severe cases, surgical interventions such as joint replacement. Osteoarthritis is one of the most prevalent musculoskeletal conditions worldwide, significantly impacting quality of life.

 

Explore the latest Osteoarthritis pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Osteoarthritis Clinical Trials

 

Emerging Osteoarthritis Drugs Under Different Phases of Clinical Development Include:

• M6495: Merck KGaA

• PPV 06: Peptinov

• LG00034053: LG Chem

• StroMel: Akan Bioscience

• TTAX03: BioTissue,Inc.

• EP-104IAR: Eupraxia Pharmaceuticals Inc.

• OLP 1002: OliPass Corporation

• JTA-004: Bone Therapeutics

• X 0002: Techfields Pharma

• Lorecivivint: Biosplice Therapeutics

 

Osteoarthritis Route of Administration

Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

 

Osteoarthritis Molecule Type

Osteoarthritis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

 

Osteoarthritis Pipeline Therapeutics Assessment

• Osteoarthritis Assessment by Product Type

• Osteoarthritis By Stage and Product Type

• Osteoarthritis Assessment by Route of Administration

• Osteoarthritis By Stage and Route of Administration

• Osteoarthritis Assessment by Molecule Type

• Osteoarthritis by Stage and Molecule Type

 

DelveInsight's Osteoarthritis Report covers around 110+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Osteoarthritis product details are provided in the report. Download the Osteoarthritis pipeline report to learn more about the emerging Osteoarthritis therapies

 

Some of the key companies in the Osteoarthritis Therapeutics Market include:

Key companies developing therapies for Osteoarthritis are - MiMedx, Flexion Therapeutics, Inc., Novartis, Techfields Pharma Co. Ltd, Celltex Therapeutics Corporation, Bioventus LLC, Saol Therapeutics Inc, Rho, Inc., Grünenthal GmbH, MiMedx Group, Inc., Biosplice Therapeutics, Nature Cell Co. Ltd., Tissue Tech Inc., Centrexion Therapeutics, Novartis, Medipost, Kolon TissueGene, Inc., Sorrento Therapeutics, Inc., Genascence Corporation, ReNu, Immunis, Inc., Taiwan Liposome Company, Akan Biosciences, LLC, Ampio Pharmaceuticals, Eli Lilly and Company, and others.

 

Osteoarthritis Pipeline Analysis:

The Osteoarthritis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoarthritis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoarthritis Treatment.

• Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoarthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Osteoarthritis drugs and therapies

 

Osteoarthritis Pipeline Market Drivers

• Rising Prevalence: Increasing cases of osteoarthritis due to aging populations and obesity are expanding the target patient pool.

• Unmet Medical Need: Current therapies mainly provide symptom relief, creating demand for disease-modifying osteoarthritis drugs (DMOADs).

• Advancements in Biologics & Regenerative Medicine: Emerging therapies such as cell-based treatments, gene therapies, and biologics offer potential for improved outcomes.

• Technological Innovations: Improved drug delivery systems and formulation technologies enhance efficacy and patient compliance.

• Growing Awareness: Increased public and physician awareness of OA management options drives market interest.

 

Osteoarthritis Pipeline Market Barriers

• High R&D Costs: Development of novel OA therapies requires significant investment and long clinical trial durations.

• Regulatory Challenges: Strict approval requirements and uncertainties in demonstrating disease-modifying effects can delay launches.

• Market Competition: Numerous generic and established therapies may limit uptake of new pipeline products.

• Clinical Trial Failures: High failure rates in late-stage trials for OA therapies can impact investor confidence.

• Reimbursement Issues: Limited insurance coverage for new or experimental therapies can restrict patient access.

 

 

Scope of Osteoarthritis Pipeline Drug Insight

• Coverage: Global

• Key Osteoarthritis Companies: Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharmaceuticals Inc., OliPass Corporation, Bone Therapeutics, Techfields Pharma, Biosplice Therapeutics M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others

• Key Osteoarthritis Therapies: M6495, PPV 06, LG00034053, StroMel, TTAX03, EP-104IAR, OLP 1002, JTA-004, X 0002, Lorecivivint, and others

• Osteoarthritis Therapeutic Assessment: Osteoarthritis current marketed and Osteoarthritis emerging therapies

• Osteoarthritis Market Dynamics: Osteoarthritis market drivers and Osteoarthritis market barriers

 

Request for Sample PDF Report for Osteoarthritis Pipeline Assessment and clinical trials

 

Table of Contents

1. Osteoarthritis Report Introduction

2. Osteoarthritis Executive Summary

3. Osteoarthritis Overview

4. Osteoarthritis- Analytical Perspective In-depth Commercial Assessment

5. Osteoarthritis Pipeline Therapeutics

6. Osteoarthritis Late Stage Products (Phase II/III)

7. Osteoarthritis Mid Stage Products (Phase II)

8. Osteoarthritis Early Stage Products (Phase I)

9. Osteoarthritis Preclinical Stage Products

10. Osteoarthritis Therapeutics Assessment

11. Osteoarthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Osteoarthritis Key Companies

14. Osteoarthritis Key Products

15. Osteoarthritis Unmet Needs

16 . Osteoarthritis Market Drivers and Barriers

17. Osteoarthritis Future Perspectives and Conclusion

18. Osteoarthritis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Index Investment Group Receives Unanimous Site Plan Approval for District Pointe Residences in West Palm Beach

We appreciate the hard work our team and City of West Palm Beach in helping bring District Pointe Residences to life, said Bjarne Borg, CEO and Executive Chairman of Index Investment Group. This development addresses the strong demand for attainable, high-quality housing offering optimal access for residents working in the city and commuters. It reflects our commitment to developing top-notch apartments in areas of demand, combining modern architecture and a true live-work-play environment.

Index Investment Group has received unanimous site plan approval from the City of West Palm Beach for District Pointe Residences, a 280-unit market-rate and workforce multifamily apartment development located on a five-acre parcel just off Belvedere Road.

West Palm Beach, FL - January 30th, 2026 - Index Investment Group has received unanimous site plan approval from the City of West Palm Beach for District Pointe Residences, a 280-unit market-rate and workforce multifamily apartment development located on a five-acre parcel just off Belvedere Road.

District Pointe Residences will be part of a thoughtfully designed, mixed-use environment that includes an office building, structured parking, and is optimized for a modern live-work-play lifestyle. The project is strategically positioned just minutes from Downtown West Palm Beach, with convenient access to major highways and the Brightline rail system and the Palm Beach International Airport.

The development will offer luxurious apartment residences at an attainable price point, providing residents with ease of access to employment centers, entertainment, and transportation hubs throughout the city.

Construction of District Pointe Residences will be led by Verdex Construction, a premier Florida-based contractor known for delivering best-in-class apartments, condominiums, and hotels. Verdex is led by industry veteran Rex Kirby.

“We appreciate the hard work of our team and the City of West Palm Beach in helping to bring District Pointe Residences to life,” said Bjarne Borg, CEO and Executive Chairman of Index Investment Group. “This development addresses the strong demand for attainable, high-quality, modern housing while offering optimal access for residents working in the city and for commuters. It reflects our continued commitment to developing top-notch apartments in areas of significant demand, combining modern architecture, thoughtful site planning, and a true live-work-play environment.”

The 280 apartment residences will feature optimized floor plans, high-end modern finishes, and accessible living options, all within close proximity to local employment centers and entertainment destinations—further supporting the continued growth of the City of West Palm Beach.

District Pointe Residences strengthens Index Investment Group’s expanding portfolio of high-quality multifamily developments and underscores the ongoing demand for attainable housing solutions throughout Palm Beach County.

For more information about Index Investment Group, please visit www.indexinvest.com and for ongoing/upcoming projects www.indexproperties.com.

About Index Investment Group

Index Investment Group is a Jupiter, Florida–based real estate investment and development firm focused on high‑quality residential, mixed‑use, and multifamily projects across premier U.S. markets. The company also invests in select industrial, office, hospitality, and renewable‑energy ventures. Known for its disciplined investment strategy, design‑driven development, and strong strategic partnerships, Index delivers projects that create long‑term value and strengthen the communities it serves.

Learn more at www.indexinvest.com.

Media Contact
Company Name: Index Investment Group
Contact Person: Joacim Borg
Email:Send Email
Phone: 561-571-0367
Address:1000 N US Hwy One Suite 902
City: Jupiter
State: Florida
Country: United States
Website: www.indexinvest.com

Thermal Spray Coating Equipment and Services Market Size, Demand Outlook, Key Trends, Strategic Opportunities, and Forecast Through 2030 | Expert Review

The Thermal Spray Coating Equipment and Services Market is witnessing steady growth, driven by demand for wear resistance, corrosion protection, and thermal performance across aerospace, automotive, and energy sectors. Key players such as Oerlikon Metco, Praxair Surface Technologies, OC Oerlikon, H.C. Starck Solutions, and Bodycote are focusing on advanced coating technologies and service expansion to strengthen their market presence.

The global thermal spray coating equipment and services market is projected to grow from USD 14.0 billion in 2024 to USD 17.8 billion by 2030, at a CAGR of 4.1% during the forecast period. The report explores comprehensive and insightful information about various key factors like regional growth, segmentation, thermal spray coating equipment and services market trends, CAGR, business revenue status of top key players and drivers. The increasing industrialization across various sectors, such as automotive, aerospace, energy, and healthcare, is a significant driver for the market. These industries require coatings to enhance their components and equipment’s performance, durability, and protection.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=193573411

By Process, the combustion flame segment accounted for the highest thermal spray coating equipment and services market share from 2024 to 2030.

By process category, the combustion flame accounts for the maximum share of the overall automotive part-cleaning service market. Using the combustion/flame process is an excellent way to control the thickness of the coating layer reasonably well. The deposition rate can be controlled, and the necessary coating thickness is achieved by adjusting variables, including fuel-to-oxygen ratio, spray distance, and traverse speed. This is crucial for maintaining uniformity across the substrate and meeting specified coating thickness requirements.

By Product, the services segment held the highest market share in the thermal spray coating equipment and services market from 2024 to 2030.

In the market for thermal spray coating equipment and services, the services segment has the largest market share. This is because there are a lot of special-use spray coatings applications, as well as technical support, maintenance, and repairs in industries such as aerospace, automotive, and energy. Therefore, they tend to be outsourced so that quality and precision can be ensured and handled by individuals who know how to do it. As a result of this demand for bundled services, including consulting and post-coating inspection, services are the foremost segment within this field.

By End-use industry, the aerospace segment accounted for the highest share of the thermal spray Coating Equipment and Services market from 2024 to 2030.

In terms of end-use sectors, aerospace accounted for the largest share. Turbine engine parts, including blades, vanes, combustor liners, and turbine casings, are coated extensively with thermal sprays. These coatings safeguard against high-temperature surroundings, oxidation, erosion, and corrosion. The main application of thermal barrier coatings (TBCs) is on turbine blades and vanes to minimize heat transfer between the blade surface and hot gas, improve fuel efficiency, and prolong the life of components. This stimulates the consumption of thermal spray coatings in the aerospace industry.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=193573411

North America is the largest thermal spray coating equipment and services market region.

One of the key factors responsible for the growth in the North American region in the Thermally Sprayed Coating Equipment and Services market is their rising adoption across different nations. Several players in this industry exist within the region; hence, it is worth noting that multiple service providers dominate these markets. Furthermore, many aerospace manufacturers in this area typically apply thermal spray coatings on aircraft engines, turbine components, aerospace structures, and other vital parts. This industry’s thirst for lightweight, anti-corrosive, high-performing coats has increased sales volumes of such products globally.

Thermal Spray Coating Equipment and Services Companies

The major players operating in the thermal spray coating equipment and services coatings market include Linde AMT (US), OC Oerlikon Management AG (Switzerland), Höganäs AB (Sweden), Saint Gobain (US), Curtiss-Wright Corporation (US), Ador Fontech Limited (India), Bodycote (UK), Curtiss-Wright Corporation (US), Kennametal, Inc. (US), Saint Gobain (US), The Lincoln Electric Company (US), A&A Thermal Spray Coatings (US), Aimtek (US), Alloy Metal Surface Technologies (India), and Wall Colmonoy (US), Hannecard (US), Brycoat Inc. (US), General Magnaplate Corporation (US), and Flame Spray Technologies BV. (Netherland) and others.

Linde AMT is a global leader serving industrial gases and engineering. It is part of Linde plc and is known for its innovative and sustainable solutions across healthcare, electronics, energy, and manufacturing. The company focuses on sophisticated materials and technology solutions, including tailored powders that fulfill precise criteria for coating and additive manufacturing applications, protecting against wear, corrosion, and high temperatures. Linde AMT also provides cutting-edge thermal spray coating equipment and services, as well as training and education programs to help customers improve operating efficiency. Their research and development are carried out at Pullach, Germany, Tonawanda, New York, Burr Ridge, Illinois, and Shanghai, with a significant geographical presence across Europe, North America, South America, the Middle East and Africa, and Asia Pacific.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=193573411

Oerlikon Metco is one of the prominent suppliers of surface solutions, serving a variety of sectors with its surface enhancement technologies and sophisticated coatings. The business offers a wide range of commodities used as their application for machinery coating, material coating and services, friction systems, and turbine components. The most recent was in March 2021, when Oerlikon Metco revealed its new enhancements to the Huntersville, North Carolina manufacturing site dedicated to providing pre- and post-coating inspection and machining services.

The Surface Technologies division of Curtiss-Wright Corporation is highly diversified and pervasive, offering the market processes in thermal spray coatings, which include HVOF, Plasma Spray, and Flame Spray. These coatings provide wear-resistant and heat-barrier solutions for essential components in high-demand industries like aircraft, energy exploration, petrochemical processing, mining, and power generation. Curtiss-Wright has manufacturing facilities in the US (Ashburn, Dayton, Farmingdale, New London, Newtown, Palmdale), Canada (Stratford), China (Suzhou, Shanghai), Germany (Garching), India (Pune), Singapore (Yishun), and the UK (Bournemouth, Cwmfelinfach). Their extensive global presence ensures that they can deliver innovative solutions across more than 100 North America, Europe, and Asia Pacific countries.

The Saint-Gobain Group is a French multinational corporation focusing on high-performance material and construction materials, including pioneering thermal and plasma spray solutions for construction, aerospace, automotive, energy, healthcare, and electronics. These solutions are critical for applications, including thermal barrier coatings and wear-resistant and corrosion-resistant coatings, as well as improving critical components' performance and longevity in high-temperature, harsh environments. Saint-Gobain Coating Solutions provides a variety of aluminum oxide thermal spray powders that result in hard, dense, and wear-resistant coatings with electrical insulating qualities. Such coatings exhibit high dielectric strength and thermal shock resistance, therefore finding application in many uses, including aerospace, automotive, chemical industries, paper, print, and textile operations. In addition, Saint-Gobain coating equipment offers a broad range of thermal spray guns, supporting equipment, and integrated thermal spray systems that provide high repair deposit efficiency and quality coatings for low-cost comprehensive protection in various applications.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/thermal-spray-coating-equipment-and-services-market-193573411.html

Collab Only Launches All in One Collaboration Platform for Creators, Products, Businesses, Streamers, Podcasters, Marketers, and Growth Partners

Collab Only

Collab Only, a new collaboration platform built for the modern content economy, has officially launched its swipe-based matchmaking platform designed to connect creators, brands, marketers, affiliates, streamers, podcasters, and product owners in one unified ecosystem. The platform helps users discover and collaborate with partners based on roles, goals, and collaboration needs, supporting the full lifecycle of content creation, promotion, and monetization. Collab Only aims to simplify collabs.

Collab Only, a new collaboration platform built for the modern content economy, today announced the official launch of its matchmaking platform designed to connect creators, products, businesses, streamers, podcasters, marketers, affiliates, and social media clippers in one unified ecosystem.

The platform introduces a swipe based matching experience that makes it easy for users to discover, connect, and collaborate with partners who help create, grow, and monetize content, products, and brands. Collab Only is built to support the full lifecycle of digital content and product promotion, from creation and distribution to monetization, audience growth, and customer acquisition.

As content creation, marketing, and digital commerce continue to expand across platforms such as YouTube, TikTok, Twitch, Instagram, podcasts, and online marketplaces, creators, marketers, products, and businesses face increasing difficulty finding the right collaborators. Collab Only addresses this challenge by enabling users to match based on roles, goals, and collaboration needs, rather than relying on cold outreach or disconnected tools.

"Content, marketing, and commerce today are team efforts," said Samuel Moreno, founder of Collab Only. Streamers need clippers, podcasters need guests and marketers, affiliates need products, businesses need creators who can drive results, and marketers need partners who can execute at scale. Collab Only brings everyone into one place and makes collaboration simple, fast, and intentional.

Collab Only supports a wide range of collaboration types, including creator and brand partnerships, product promotions, streamer and clip creator collaborations, podcast guest bookings, content distribution, affiliate partnerships, performance based campaigns, marketing collaborations, and cross creator collaborations.

Users can create profiles, browse potential matches, and unlock in app messaging once both parties show interest. The platform is designed to be intuitive, mobile first, and accessible to users at any stage, whether they are established professionals or just getting started.

The platform launches with support for creators, marketers, products, and businesses across major social, content, and commerce platforms and will continue expanding features focused on collaboration discovery, growth tools, and monetization opportunities.

Collab Only is available starting January 30, 2026, at https://collabonly.com. Creators, product owners, businesses, marketers, and growth partners can sign up today and begin matching with collaborators worldwide.

Media Contact
Company Name: Collab Only
Contact Person: Samuel Moreno
Country: United States
Website: https://collabonly.com

Focal Segmental Glomerulosclerosis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | B. Braun Melsungen, Beckman Coulter (Danaher), Baxter

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Focal Segmental Glomerulosclerosis pipeline constitutes 15+ key companies continuously working towards developing 18+ Focal Segmental Glomerulosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Focal Segmental Glomerulosclerosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Focal Segmental Glomerulosclerosis Market.

 

The Focal Segmental Glomerulosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Get a Free Sample PDF Report to know more about Focal Segmental Glomerulosclerosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-pipeline-insight

 

Some of the key takeaways from the Focal Segmental Glomerulosclerosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Focal Segmental Glomerulosclerosis treatment therapies with a considerable amount of success over the years.

• Focal Segmental Glomerulosclerosis companies working in the treatment market are Dimerix Bioscience, Travere Therapeutics, Walden Biosciences, ZyVersa Therapeutics, Sanofi, and others, are developing therapies for the Focal Segmental Glomerulosclerosis treatment

• Emerging Focal Segmental Glomerulosclerosis therapies in the different phases of clinical trials are- DMX-200, Sparsentan, WAL0921, VAR 200-01, Brivekimig, and others are expected to have a significant impact on the Focal Segmental Glomerulosclerosis market in the coming years.

• In January 2026, Travere Therapeutics’ effort to secure an expanded approval for Filspari in treating focal segmental glomerulosclerosis (FSGS) carries significant stakes, with the U.S. market alone projected at a $2 billion peak sales opportunity, according to Leerink Partners. The San Diego-based rare disease company recently announced, however, that the FDA has delayed its decision on Filspari for FSGS by three months, now expected by April 13.

• In November 2025, Travere Therapeutics, Inc. (Nasdaq: TVTX) announced new findings from the Phase 3 DUPLEX Study showing that patients with focal segmental glomerulosclerosis (FSGS) treated with FILSPARI® (sparsentan) were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those treated with the highest approved dose of irbesartan. Reaching this proteinuria threshold was associated with a lower risk of progressing to kidney failure. The results were shared in a late-breaking poster presentation at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston.

• In June 2025, The DUPLEX trial (NCT03493685) found that the dual endothelin-angiotensin receptor antagonist sparsentan led to a sustained decrease in proteinuria in patients with focal segmental glomerulosclerosis (FSGS).

• In May 2025, Travere Therapeutics, Inc. revealed that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking traditional approval for FILSPARI (sparsentan) to treat focal segmental glomerulosclerosis (FSGS).

• In April 2025, Dimerix Limited and Amicus Therapeutics announced they have signed an exclusive licensing agreement for the U.S. commercialization of Dimerix’s Phase III drug candidate DMX-200 for all indications, including FSGS. Dimerix will retain all rights to commercialize DMX-200 in territories outside those covered by the exclusive U.S. license

• In January 2025, Dimerix entered into an exclusive development and licensing agreement with Fuso Pharmaceutical Industries Pty Ltd in Japan for the development and commercialization of its ACTION3 Phase III drug candidate, DMX-200, aimed at treating focal segmental glomerulosclerosis (FSGS) kidney disease.

 

Focal Segmental Glomerulosclerosis Overview

The hallmark of focal and segmental obliteration of glomerular capillary tufts inside enlarged matrix is known as focal segmental glomerular sclerosis (FSGS). FSGS is categorized based on the location and nature of the sclerotic lesion into collapsing, tip, cellular, perihilar, and not otherwise defined forms.

 

Explore the latest Focal Segmental Glomerulosclerosis pipeline insights 2025, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Focal Segmental Glomerulosclerosis Clinical Trials

 

Emerging Focal Segmental Glomerulosclerosis Drugs Under Different Phases of Clinical Development Include:

• Research programme Oligonucleotides: Ceptur Therapeutics

• EG-102: Evergreen Therapeutics

• D4-101-02: Delta4

• OCX-063: Certa Therapeutics

• BI764198: Boehringer Ingelheim

• R3R 01: River 3 Renal Corp

• DMX-200: Dimerix Bioscience

• Sparsentan: Travere Therapeutics, Inc.

 

Focal Segmental Glomerulosclerosis Route of Administration

Focal Segmental Glomerulosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Intravenous

• Subcutaneous

• Intramuscular

 

Focal Segmental Glomerulosclerosis Molecule Type

Focal Segmental Glomerulosclerosis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

 

Focal Segmental Glomerulosclerosis Pipeline Therapeutics Assessment

• Focal Segmental Glomerulosclerosis Assessment by Product Type

• Focal Segmental Glomerulosclerosis By Stage and Product Type

• Focal Segmental Glomerulosclerosis Assessment by Route of Administration

• Focal Segmental Glomerulosclerosis By Stage and Route of Administration

• Focal Segmental Glomerulosclerosis Assessment by Molecule Type

• Focal Segmental Glomerulosclerosis by Stage and Molecule Type

 

DelveInsight's Focal Segmental Glomerulosclerosis Report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further Focal Segmental Glomerulosclerosis product details are provided in the report. Download the Focal Segmental Glomerulosclerosis pipeline report to learn more about the emerging Focal Segmental Glomerulosclerosis therapies

 

Some of the key companies in the Focal Segmental Glomerulosclerosis Therapeutics Market include:

Key companies developing therapies for Focal Segmental Glomerulosclerosis are - B. Braun Melsungen AG, Beckman Coulter Inc. (Danaher), Baxter International Inc., ChemoCentryx Inc., Complexa Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Retrophin Inc., Variant Pharmaceuticals Inc., and others.

 

Focal Segmental Glomerulosclerosis Pipeline Analysis:

The Focal Segmental Glomerulosclerosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Focal Segmental Glomerulosclerosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Focal Segmental Glomerulosclerosis Treatment.

• Focal Segmental Glomerulosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Focal Segmental Glomerulosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Focal Segmental Glomerulosclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Focal Segmental Glomerulosclerosis drugs and therapies

 

Focal Segmental Glomerulosclerosis Pipeline Market Drivers

• Surge of interest in developing new therapies for FSGS, renaissance in clinical research in nephrology are some of the important factors that are fueling the Focal Segmental Glomerulosclerosis Market.

 

Focal Segmental Glomerulosclerosis Pipeline Market Barriers

• However, the etiology and pathogenesis of Focal Segmental Glomerulosclerosis are very complex, high cost associated with the disease and other factors are creating obstacles in the Focal Segmental Glomerulosclerosis Market growth.

 

Scope of Focal Segmental Glomerulosclerosis Pipeline Drug Insight

• Coverage: Global

• Key Focal Segmental Glomerulosclerosis Companies: Dimerix Bioscience, Travere Therapeutics, Walden Biosciences, ZyVersa Therapeutics, Sanofi, and others

• Key Focal Segmental Glomerulosclerosis Therapies: DMX-200, Sparsentan, WAL0921, VAR 200-01, Brivekimig, and others

• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies

• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers

 

Request for Sample PDF Report for Focal Segmental Glomerulosclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Focal Segmental Glomerulosclerosis Report Introduction

2. Focal Segmental Glomerulosclerosis Executive Summary

3. Focal Segmental Glomerulosclerosis Overview

4. Focal Segmental Glomerulosclerosis- Analytical Perspective In-depth Commercial Assessment

5. Focal Segmental Glomerulosclerosis Pipeline Therapeutics

6. Focal Segmental Glomerulosclerosis Late Stage Products (Phase II/III)

7. Focal Segmental Glomerulosclerosis Mid Stage Products (Phase II)

8. Focal Segmental Glomerulosclerosis Early Stage Products (Phase I)

9. Focal Segmental Glomerulosclerosis Preclinical Stage Products

10. Focal Segmental Glomerulosclerosis Therapeutics Assessment

11. Focal Segmental Glomerulosclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Focal Segmental Glomerulosclerosis Key Companies

14. Focal Segmental Glomerulosclerosis Key Products

15. Focal Segmental Glomerulosclerosis Unmet Needs

16 . Focal Segmental Glomerulosclerosis Market Drivers and Barriers

17. Focal Segmental Glomerulosclerosis Future Perspectives and Conclusion

18. Focal Segmental Glomerulosclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/